Pancreatic Cancer

• Body composition factor is independent prognosticator in <break/>advanced pancreatic cancer patients
• Early detection of skeletal muscle atrophy using a multiple <break/>plasma-free amino acid index in the advanced aged patients with advanced pancre...
• Referral patterns and predictors of survival for stage IV pancreatic ductal adenocarcinoma
• Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)
• SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine &#x0002B;/-nelfinavir with high or standard dose radio...
• A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer
• Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer
• First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine&#x0002B;nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic aden...
• Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic ca...
• Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC):...
• FOLFIRINOX for recurrent pancreatic cancer after resection: Nationwide multicenter observational study by Japan adjuvant study group of pancreatic...
• A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
• Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis
• Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus...
• A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy ana...
• Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a fami...
• GEMOX plus hypofractionated radiotherapy for unresectable locally advanced pancreatic cancer: Results from a phase II study
• NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
• Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology cli...
• Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): F...
• A phase II trial of gemcitabine, S-1 and LV combination therapy in patients with advanced pancreatic cancer
• Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer
• Quality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the la...
• Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally adva...
• Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC)...

• « Previous
• 1
• 2
• ...
• 19
• Next »